行业聚焦：全球过敏类疾病靶向药物市场头部企业份额调研（附Top 10 厂商名单）

Core Viewpoint - The targeted drug market for allergic diseases is rapidly evolving due to increased understanding of immune pathways and the rising burden of allergic diseases globally, with a focus on precision medicine and innovative therapies [3][4]. Group 1: Definition and Overview - Allergic diseases affect approximately 25% of the global population, with type 2 immune pathway abnormalities being a significant factor in their development [2]. - Targeted drugs, including biologics and small molecule inhibitors, are becoming mainstream in the treatment of allergic diseases, showing better efficacy and safety compared to traditional therapies [2][3]. Group 2: Market Development - The market for targeted drugs is expanding from monoclonal antibodies to a diverse range of biologics and small molecule inhibitors, with several products already approved for conditions like asthma and atopic dermatitis [4]. - Major pharmaceutical companies and emerging biotech firms are actively participating in this market, driving innovation and expanding treatment indications [4]. Group 3: Future Trends - Future drug development will focus on new mediators related to allergic inflammation, such as IL-33, and will integrate precision medicine approaches to enhance treatment efficacy [5]. - The market is expected to see a rise in small molecule therapies and oral treatments, providing more convenient administration options [5]. Group 4: SWOT Analysis - Strengths include a solid scientific foundation based on advances in immunology and molecular biology, leading to effective targeted therapies [6]. - Opportunities arise from the increasing prevalence of allergic diseases and the potential for new targets and combination therapies [8]. Group 5: Market Size and Competition - The global market for targeted drugs for allergic diseases is projected to reach approximately $37.15 billion by 2024, with a compound annual growth rate (CAGR) of 16.07% [10]. - Major manufacturers like Sanofi, AbbVie, and Novartis hold about 76.09% of the market share, with IL-4R being the leading product type [12][14]. Group 6: Regional Market Insights - North America leads the market due to advanced healthcare systems and high patient awareness, while Europe shows strong growth supported by regulatory frameworks [20]. - Emerging markets, particularly in Asia, are experiencing rapid growth due to rising prevalence and expanding healthcare coverage [20].